Identifying Risk Factors for Colorectal and Breast Cancer in Nigeria
Official title: Case Control Study to Identify Modifiable Risk Factors for Colorectal and Breast Cancer in Nigeria
Run by Obafemi Awolowo University Teaching Hospital · NCT05044689 · Data updated 2026-11-12
This study is trying to find out what lifestyle and health factors might increase the risk of colorectal and breast cancer in people in Nigeria.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 800 (estimated) |
| Sponsor | Obafemi Awolowo University Teaching Hospital Academic / other |
| Locations | 1 site (Ile-Ife, Osun State) |
| Status | Recruiting |
| Started | April 12, 2021 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | March 21, 2025 |
| Trial ID | NCT05044689 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals with a confirmed diagnosis of colorectal or breast cancer for the case group, and healthy individuals without cancer for the control group.
✕Probably not a fit
Patients with other types of cancer or those with gastrointestinal diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational case-control study aims to identify modifiable risk factors associated with colorectal and breast cancer in Nigeria. Participants will include 400 patients with confirmed diagnoses of these cancers and 400 controls without cancer or gastrointestinal diseases. Both groups will complete a risk factor questionnaire covering diet, physical activity, medical history, and lifestyle factors, and will undergo body composition analysis using a bioimpedance machine. The study seeks to uncover insights that could lead to preventive strategies against these cancers.
Why it matters
Potential benefit: If successful, this study could help identify lifestyle changes that may reduce the risk of colorectal and breast cancer in the Nigerian population.
How similar studies have gone: Similar studies have successfully identified risk factors for various cancers, suggesting that this approach could yield valuable insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Case Group - Patients must have histologically confirmed diagnosis of colorectal or breast cancer. Control Group - Patients must not have a diagnosis of cancer.
Where it's running
-
Obafemi Awolowo University Teaching Hospitals
Ile-Ife, Osun State, Nigeria Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
First-in-human STRO-006 in adults with certain recurrent or metastatic solid tumors
This study tests STRO-006 alone and with pembrolizumab in adults with certain head and neck, lung, esophageal, gastric, colorectal cancers to see if it is safe and shows early anticancer activity.
-
Prospective look at liver metastases imaging and tissue patterns in colorectal and breast cancer
This observational study tests whether 3D maps of histopathological growth patterns in liver metastases align with imaging features from MRI/CT in patients undergoing liver surgery.
-
Oral, Fecal and Tumor Microbiome Atlas in Colombian Patients With Advanced Solid Tumors Receiving First-Line Immunotherapy
This study tests how the oral, gut, and tumor microbiomes relate to response to first-line immunotherapy in Colombian adults with advanced solid cancers.
-
Precision navigation to boost cancer screening participation in high-risk communities
This study tests whether a personalized navigation program helps adults aged 45–74 in Chinese communities who are at high risk for several cancers to complete recommended free cancer screenings.
-
Targeted radiopharmaceuticals for GRPR-positive cancers in adults
A phase 1 study tests two targeted radiopharmaceuticals, radiolabeled Lu-177 and Ac-225 compounds, to treat GRPR-expressing breast, prostate, colorectal, and other solid tumors in adults who have not benefited from standard therapies.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.